Navigation Links
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
Date:9/19/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") today announced a discussion on CEOLIVE.TV by Jeffrey Bacha, president and CEO of DelMar Pharma, a cancer-focused company developing new therapies for patients with little to no treatment options. DelMar's first drug in development is VAL-083, a potential first-in-class treatment for glioblastoma multiforme (GBM). 

Mr. Bacha will also discuss how the company is strategically advancing VAL-083 in the U.S., where the drug is in encouraging Phase I/II clinical trials for glioblastoma, and in China, where the drug is currently approved to treat lung cancer and chronic myelogenous leukemia (CML).

Watch the interview here: http://www.ceolive.tv/delmarpharma

Quotes:

Jeffrey Bacha, president and CEO of DelMar Pharma, "We are testing VAL-083 in glioblastoma, where there is the greatest need and greatest potential impact, and we are running our studies as quickly as possible to get this promising drug into the hands of physicians to treat the patients who need it the most."

Key Facts:

  • More than 15,000 people are diagnosed with glioblastoma each year in the U.S.
  • Approximately half of glioblastoma patients will fail the approved therapies
  • Many patients develop resistance to the front-line therapy, Temodar® ($950 million annual sales), because of an enzyme known as MGMT
  • VAL-083 acts through a mechanism independent of MGMT
  • Interim clinical trial results presented at ASCO suggest VAL-083 may have an improved safety and dosing profile over current therapies
  • Studies by the National Cancer Institute and DelMar have shown VAL-083 to have activity against a range of cancers, including glioblastoma
  • DelMar is conducting a Phase I/II clinical trial for VAL-083 at UC San Francisco and the Sarah Cannon Research Institute in Nashville, Tennessee and Sarasota, Florida
  • VAL-083 has received orphan drug designation in Europe and the U.S.

Additional Information:

About DelMar Pharmaceuticals

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For more information, please visit www.delmarpharma.com or follow us on Twitter @delmarpharma

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

 


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... Global  urinalysis market  is ... 2022, according to a new report by Grand ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation is ... accuracy delivered by the new generation urinalysis devices ... instruments and consumables. For instance, the automatic bench-top ...
(Date:4/26/2016)... Holdings, Inc. (NYSE: HRC ) invites you to ... st Annual Health Care Conference on Wednesday, May 4, ... to listen to the live discussion via the internet link ... http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion will be ... accessible at the links above until August 1, 2016. ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Point Source ... microphones and headsets announced today that the US Patent Office has approved its ... a structure. This innovative design creates a lightweight and modular audio headset that ...
(Date:4/28/2016)... Tamarac, FL (PRWEB) , ... April 28, 2016 , ... ... body recovery supplement GlycoLoad at this week’s 2016 Europa Games Get Fit and ... health conscious consumers alike, the Europa Orlando Expo coming up April 29-30, was selected ...
(Date:4/28/2016)... Washington, D.C. (PRWEB) , ... April 28, 2016 , ... ... Control and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition ... by the medical community effective October 1, 2016. , Sarcopenia is defined as a ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... health insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing ... FDA-approved prescription medications from over 180 American pharmaceutical companies for $35 per ...
Breaking Medicine News(10 mins):